Brief: Quince Therapeutics Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
08/12/2023 21:18
Dec 9 (Reuters) - Quince Therapeutics Inc QNCX.O :
* QUINCE THERAPEUTICS: ON DECEMBER 4, 2023 RECEIVED NOTICE
OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges